Dr. Andrew Patel and Oath Surgical Bring Sleep Apnea Implant to Oregon in a First for Pacific Northwest Outpatient Surgery
Oath Surgical's Portland-based AI-native surgical center becomes the first in the Pacific Northwest to deliver bilateral HGNS therapy in an ambulatory surgery center setting
Oath Surgical today announced that Dr. Andrew Patel has performed the first of its kind implant procedure in Oregon and the first in the Pacific Northwest to take place in an ambulatory surgery center (ASC) setting. The milestone expands access to an innovative treatment option in a state where an estimated 1.1 million residents, or 31% of the population, have mild to severe obstructive sleep apnea (OSA), including approximately 165,000 people in Portland.
Genio, developed by Nyxoah, is an FDA-approved therapy for moderate to severe obstructive sleep apnea. It is the first single-incision bilateral hypoglossal nerve stimulation (HGNS) therapy, with no implanted battery and full 3T MRI compatibility, designed to treat sleep apnea by working with the body's natural bilateral airway control system.
The procedure was performed at Oath Surgical's downtown Portland, Oregon facility, one of three AI-native outpatient surgical centers the company owns and operates in the region. Oath uses its purpose-built OathOS clinical intelligence system to support these advanced implant procedures in an outpatient setting. OathOS connects every step of the patient journey, from referral and scheduling through device activation, outcomes tracking, and long-term post-operative engagement, into a single unified system.
